Trevena (NASDAQ:TRVN – Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01, reports. The company had revenue of $0.02 million during the quarter.
Trevena Price Performance
Shares of TRVN stock opened at $0.41 on Friday. Trevena has a 12 month low of $0.30 and a 12 month high of $1.35. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 8.35. The stock has a 50 day moving average of $0.44 and a 200-day moving average of $0.56.
Analyst Ratings Changes
Several analysts recently issued reports on TRVN shares. HC Wainwright decreased their price objective on shares of Trevena from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. StockNews.com assumed coverage on Trevena in a research report on Thursday. They issued a “sell” rating on the stock.
Hedge Funds Weigh In On Trevena
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new position in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent filing with the Securities and Exchange Commission. 13.56% of the stock is owned by hedge funds and other institutional investors.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
See Also
- Five stocks we like better than Trevena
- 3 Tickers Leading a Meme Stock Revival
- Analysts Still Want Double-Digit Upside Out of Applied Materials
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Baidu Stock Earnings Prove Ray Dalio Right about China?
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Reasons Nvidia is on The Verge of a 4 Digit Stock Price
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
